Clinical studies with blinatumomab, showing a high response and relapse-free survival rate among adults with CD19+ acute lymphoblastic leukemia (ALL) that persisted or relapsed after chemotherapy [23–25], suggest the potential of these molecules for acute leukemias. This evidence concerns the gene CD19 and acute leukemia.